179 filings
Page 3 of 9
8-K
9lkr0b z184xe
5 Dec 23
Clinical development plan potentially leveraging 505(b)(2) regulatory pathway
9:07am
CORRESP
r8xx zqgbkzufnoks5k7
4 Dec 23
Correspondence with SEC
12:00am
8-K
54i0j1 9iq5ej
27 Nov 23
Clinical development plan leveraging 505(b)(2) regulatory pathway
8:38am
8-K
8ub 5xk77t
24 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:04pm
UPLOAD
c4y22vbbvmjtazay
21 Nov 23
Letter from SEC
12:00am
8-K
75rth03euf11 7zrw1ih
15 Nov 23
Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis ("IPF") on track to start before year end 2023; Interim data expected H1 2024
8:07am
8-K
z25wyk
1 Nov 23
Regulation FD Disclosure
8:45am
8-K
rphkec4899
25 Aug 23
Regulation FD Disclosure
4:42pm
8-K
9ka5g
23 Aug 23
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR
9:07am
8-K
9he79k7p3m2exizdrx2l
14 Aug 23
On track to launch a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF before year end 2023
8:06am
8-K
xeqbud7g5b3 gt2a
7 Jul 23
Submission of Matters to a Vote of Security Holders
4:03pm
8-K/A
c2cva37m 2n
6 Jul 23
Financial Statements and Exhibits
4:28pm
EFFECT
1kfm71yi 57csj
8 Jun 23
Notice of effectiveness
12:15am
424B3
xw8zra
7 Jun 23
Prospectus supplement
4:18pm
CORRESP
e5kstvnafjqn6caj
5 Jun 23
Correspondence with SEC
12:00am
UPLOAD
9gahovflqj5
5 Jun 23
Letter from SEC
12:00am